Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular's HT-LP Included in 2017 Shanghai Innovative Product Recommendation List


Shanghai, China – Hercules™-T Low Profile Stent-Graft ("HT-LP"), in-house developed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was recently included in the 2017 Shanghai Innovative Product Recommendation List ("Recommendation List") according to an announcement recently released by Shanghai Municipal Commission of Economy and Informatization. Such honor is expected to benefit the commercialization and industrialization of HT-LP.
The Recommendation List is designed to facilitate the implantation of Shanghai government's innovation-driven strategies to build a technological innovation center in the city. The Recommendation List is expected to provide references to decision makers of government purchasing to encourage and facilitate the development and application of innovative products. The product selected into this year’s list were also included in the government purchasing project system for their major innovation, independent intellectual property, great potential for economic benefits and promising market prospect. This year, only 66 products were included in the Recommendation List.
HT-LP is built on the success of Hercules® Thoracic Stent-Graft System. It is designed for the endovascular treatment of descending thoracic aortic disease. HT-LP has significant advantages in outer diameter and cross arch ability compared to similar products on the market. It is the first thoracic aortic aneurysm ("TAA") stent to have low profile delivery system with 18F outer diameter, the lowest among aortic stents in the world, which would benefit patients with narrow introducing femoral artery, mostly Asian female patients. Its soft inner sleeves are made of PET, which makes it easier for the stent to cross the aortic arch. The rear release mechanism of bare stent leads to more precise and stable positioning and deployment. The product offers 0-10mm taper availability, in accordance with the pathological features of aortic dissection. The height-mutative main body stent improves the flexibility of the whole stent.
MicroPort® Endovascular will continue to build a technology innovation system, actively carry out the transformation of scientific research achievement, and enhance independent innovation, integrated innovation and cooperative innovation, so as to offer more safe, effective, high quality and affordable high-end medical devices to patients and help drive the development of Shanghai's innovative technology.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® EP's Contact Force Sensing RF Ablation Catheter Gains CFDA Green-Path
[Next]:MicroPort® Enters into Binding Letter of Intent to Buy Cardiac Rhythm Management Business Franchise from LivaNova for $190 Million